Short- versus long-course antibacterial therapy for community-acquired pneumonia: A meta-analysis

Drugs

Volumn 68, Issue 13, 2008, Pages 1841-1854

  Dimopoulos, George ^a,b   Matthaiou, Dimitrios K ^a   Karageorgopoulos, Drosos E ^a   Grammatikos, Alexandros P ^c   Athanassa, Zoe ^a   Falagas, Matthew E ^a,d,e  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c G GENNIMATAS GENERAL HOSPITAL   (Greece)

^d HENRY DUNANT HOSPITAL   (Greece)

^e TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibacterials, therapeutic use; Community acquired pneumonia, treatment; Meta analysis

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; CEFTRIAXONE; CEFUROXIME; GEMIFLOXACIN; PARACETAMOL; SALBUTAMOL; TELITHROMYCIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FIXED EFFECT MODEL; FOLLOW UP; HUMAN; INFANT; LONG TERM CARE; META ANALYSIS; MODEL; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; ANTI-BACTERIAL AGENTS; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; INFANT; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 50249172762     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868130-00004     Document Type: Article

References (47)

1. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in eastern Finland. Am J Epidemiol 1993; 137: 977-88
2. Schappert SM, Burt CW. Ambulatory care visits to physician offices, hospital outpatient departments, and emergency departments: United States, 2001-02. Vital Health Stat 2006; 13: 1-66
3. National Center for Health Statistics. Health, United States, 2006, with chartbook on trends in the health of Americans [online]. Available from URL: http://www.cdc.gov/nchs/data/hus/hus06.pdf [Accessed 2007 Nov 7]
4. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50
5. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82
6. Guest JF, Morris A. Community-acquired pneumonia: the annual cost to the National Health Service in the UK. Eur Respir J 1997; 10: 1530-4
7. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
8. Niederman MS, McCombs JS, Unger AN, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-37
9. Oosterheert JJ, Bonten MJ, Schneider MM, et al. Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial. BMJ 2006; 333: 1193-5
10. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54
11. Li JZ, Winston LG, Moore DH, et al. Efficacy of short-course antibiotic regimens for community-acquired pneumonia: a meta-analysis. Am J Med 2007; 120: 783-90
12. Schentag JJ, Ballow CH. Tissue-directed pharmacokinetics. Am J Med 1991; 91: 5-11S
13. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-60
14. Khan KS, Daya S, Jadad A. The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 1996; 156: 661-6
15. Moher D, Jadad AR, Tugwell P. Assessing the quality of randomized controlled trials: current issues and future directions. Int J Technol Assess Health Care 1996; 12: 195-208
16. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. Stat Med 2004; 23: 1663-82
17. Fletcher J. What is heterogeneity and is it important? BMJ 2007; 334: 94-6
18. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-48
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88
20. File Jr TM, Mandell LA, Tillotson G, et al. Gemifloxacin once daily for 5 days versus 7 days for the treatment of community-acquired pneumonia: a randomized, multicentre, double-blind study. J Antimicrob Chemother 2007; 60: 112-20
21. El Moussaoui R, de Borgie CA, van den Broek P, et al. Effectiveness of discontinuing antibiotic treatment after three days versus eight days in mild to moderate-severe community acquired pneumonia: randomised, double blind study. BMJ 2006; 332: 1355
22. Agarwal G, Awasthi S, Kabra SK, et al. Three day versus five day treatment with amoxicillin for non-severe pneumonia in young children: a multicentre randomised controlled trial. BMJ 2004; 328: 791
23. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. J Antimicrob Chemother 2004; 54: 515-23
24. Leophonte P, Choutet P, Gaillat J, et al. Efficacy of a ten day course of ceftriaxone compared to a shortened five day course in the treatment of community-acquired pneumonia in hospitalized adults with risk factors. Med Mal Infect 2002; 32: 369-81
25. Pakistan Multicentre Amoxycillin Short Course Therapy (MASCOT) pneumonia study group. Clinical efficacy of 3 days versus 5 days of oral amoxicillin for treatment of childhood pneumonia: a multicentre double-blind trial. Lancet 2002; 360: 835-41
26. Siegel RE, Alicea M, Lee A, et al. Comparison of 7 versus 10 days of antibiotic therapy for hospitalized patients with uncomplicated community-acquired pneumonia: a prospective, randomized, double-blind study. Am J Ther 1999; 6: 217-22
27. Casey JR, Pichichero ME. Metaanalysis of short course antibiotic treatment for group a streptococcal tonsillopharyngitis. Pediatr Infect Dis J 2005; 24: 909-17
28. Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290: 2588-98
29. Kozyrskyj AL, Hildes-Ripstein GE, Longstaffe SE, et al. Treatment of acute otitis media with a shortened course of antibiotics: a meta-analysis. JAMA 1998; 279: 1736-42
30. Montravers P, Fagon JY, Chastre J, et al. Follow-up protected specimen brushes to assess treatment in nosocomial pneumonia. Am Rev Respir Dis 1993; 147: 38-44
31. Awunor-Renner C. Length of antibiotic therapy in in-patients with primary pneumonias. Ann Trop Med Parasitol 1979; 73: 235-40
32. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44 Suppl. 2: S27-72
33. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA 1998; 279: 1452-7
34. Metlay JP, Atlas SJ, Borowsky LH, et al. Time course of symptom resolution in patients with community-acquired pneumonia. Respir Med 1998; 92: 1137-42
35. Menendez R, Torres A, Rodriguez de CF, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-90
36. File Jr TM. Clinical efficacy of newer agents in short-duration therapy for community-acquired pneumonia. Clin Infect Dis 2004; 39 Suppl. 3: S159-64
37. Fine MJ, Stone RA, Singer DE, et al. Processes and outcomes of care for patients with community-acquired pneumonia: results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study. Arch Intern Med 1999; 159: 970-80
38. Branthwaite A, Pechere JC. Pan-European survey of patients' attitudes to antibiotics and antibiotic use. J Int Med Res 1996; 24: 229-38
39. Hoppe JE, Blumenstock G, Grotz W, et al. Compliance of German pediatric patients with oral antibiotic therapy: results of a nationwide survey. Pediatr Infect Dis J 1999; 18: 1085-91
40. Reyes H, Guiscafre H, Munoz O, et al. Antibiotic noncompliance and waste in upper respiratory infections and acute diarrhea. J Clin Epidemiol 1997; 50: 1297-304
41. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286: 49-56
42. Guillemot D, Carbon C, Balkau B, et al. Low dosage and long treatment duration of beta-lactam: risk factors for carriage of penicillin-resistant Streptococcus pneumoniae. JAMA 1998; 279: 365-70
43. World Health Organization. Acute respiratory infections in children [online]. Available from URL: http://www.who.int/fch/depts/cah/resp_infections/ en/ [Accessed 2007 Nov 7]
44. British Thoracic Society Guidelines for the management of community acquired pneumonia in childhood. Thorax 2002; 57 Suppl. 1: i1-24
45. McIntosh K. Community-acquired pneumonia in children. N Engl J Med 2002; 346: 429-37
46. Shann F. Etiology of severe pneumonia in children in developing countries. Pediatr Infect Dis 1986; 5: 247-52
47. Weber MW, Mulholland EK, Greenwood BM. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 1998; 3: 268-80